跳至主要内容
临床试验/NCT01508143
NCT01508143已完成不适用

A Comparative Study of Vaginal Misoprostol Two Dosing Regimen for First Trimester Pregnancy Termination in Patients Admitted at Bandarabbas in Shariati Hospital in 2009

Hormozgan University of Medical Sciences1 个研究点 分布在 1 个国家目标入组 41 人开始时间: 2012年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
41
试验地点
1
主要终点
Abortion

研究概览

简要总结

The aim of this study is to compare two misoprostol regimen in pregnancy termination.

详细描述

Studies on determining the optimal dosage for misoprostol in pregnancy termination are continuing and still there is no evidence for ideal misoprostol regimen for pregnancy termination. The aim of this study is to compare two misoprostol regimen in pregnancy termination.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

性别
Female
接受健康志愿者

入选标准

  • All women who were candidates for early pregnancy termination because of fetal death or other medical conditions
  • Before 14th week of gestation calculated according LMP or first trimester sonography

排除标准

  • Chorioamnionitis
  • Hypersensitivity to prosstaglandins
  • Past medical history of cardiovascular, kidney or liver or lung diseases
  • Positive history for uterus pathologies
  • suspicious to extra-uterus pregnancy
  • sign and symptoms of uterus infection
  • Molar pregnancy

研究组 & 干预措施

400 microgram misoprostol

Experimental

400 micrograms misoprostol each 6 hours for 8 dose

干预措施: Misoprostol 400 micrograms (Drug)

800 micrograms misoprostol

Active Comparator

800 micrograms misoprostol each 12 hours for 4 dose

干预措施: Misoprostol 800 micrograms (Drug)

结局指标

主要结局

Abortion

时间窗: 48 hours after treatment

After 48 hours after treatment each patient is assessed for abortion. Patients are devided into three groups including complete, partial or no abortion.

次要结局

  • Duration of abortion(Form the begining of treatment to complete abortion)
  • Adverse Effects(48 hours after treatment)
  • Need for surgery(48 hours after treatment)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Hamidreza Mahboobi

Medical Doctor

Hormozgan University of Medical Sciences

研究点 (1)

Loading locations...

相似试验